Liquidia (LQDA) Cash from Financing Activities (2020 - 2026)
Liquidia (LQDA) posted quarterly Cash from Financing Activities of -$18.1 million for Q1 2026, down 174.33% year-over-year from $24.3 million in Q1 2025, and down 157.11% quarter-over-quarter from -$7.0 million in Q4 2025.
Liquidia (LQDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Liquidia's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$18.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 174.33% year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at $17.4 million (down 85.43% YoY), while the FY2025 annual figure was $59.7 million, down 69.32% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$18.1 million, down from -$7.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $99.7 million in Q1 2024, with the low at -$18.1 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $10.0 million (2023), against an average of $20.3 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 41377.19% in 2023, then slumped 205.84% in 2025.
- Liquidia's Cash from Financing Activities stood at $57000.0 in 2022, then soared by 41377.19% to $23.6 million in 2023, then sank by 109.71% to -$2.3 million in 2024, then plunged by 205.84% to -$7.0 million in 2025, then plunged by 157.11% to -$18.1 million in 2026.
- Business Quant data shows LQDA's Cash from Financing Activities at -$18.1 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn | -6.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.61 Mn |
| Jun 30, 2026 | -6.61 Mn |
| Mar 31, 2026 | -18.05 Mn |
| Mar 31, 2026 | -18.05 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Jun 30, 2025 | 47.71 Mn |
| Jun 30, 2025 | 47.71 Mn |
| Mar 31, 2025 | 24.29 Mn |
| Mar 31, 2025 | 24.29 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Sep 30, 2024 | 98.10 Mn |
| Sep 30, 2024 | 98.10 Mn |
| Jun 30, 2024 | -814,000.00 |
| Jun 30, 2024 | -814,000.00 |
| Mar 31, 2024 | 99.67 Mn |
| Mar 31, 2024 | 99.67 Mn |